Applied Molecular Transport Stock News

Marshall Wace LLP bought a new position in shares of Applied Molecular Transport Inc. (NASDAQ:AMTI) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 8,441 shares of the companys stock, valued at approximately $386,000. Several other institutional investors have also added to or reduced their stakes in AMTI. FMR LLC acquired a new stake []

Shares of Applied Molecular Transport Inc. (NASDAQ:AMTI) dropped 14.5% on Friday . The company traded as low as $16.18 and last traded at $16.23. Approximately 4,597 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 169,544 shares. The stock had previously closed at $18.99. AMTI has been the []

Applied Molecular Transport Inc. (NASDAQ:AMTI) shares hit a new 52-week low during trading on Monday . The stock traded as low as $20.35 and last traded at $20.35, with a volume of 222 shares traded. The stock had previously closed at $21.45. Several brokerages recently commented on AMTI. Jefferies Financial Group began coverage on shares []

Applied Molecular Transport Inc. (NASDAQ:AMTI) major shareholder Epiq Capital Group, Llc acquired 4,000 shares of the firms stock in a transaction dated Tuesday, November 16th. The stock was bought at an average price of $22.57 per share, with a total value of $90,280.00. The acquisition was disclosed in a legal filing with the SEC, which []

Applied Molecular Transport Inc. (NASDAQ:AMTI) Investment analysts at SVB Leerink decreased their FY2021 earnings estimates for Applied Molecular Transport in a report issued on Wednesday, November 10th. SVB Leerink analyst J. Schwartz now expects that the company will earn ($2.57) per share for the year, down from their prior estimate of ($2.48). SVB Leerink []

Applied Molecular Transport Inc. (NASDAQ:AMTI) Stock analysts at SVB Leerink reduced their FY2021 earnings estimates for Applied Molecular Transport in a research note issued on Wednesday, November 10th. SVB Leerink analyst J. Schwartz now expects that the company will post earnings per share of ($2.57) for the year, down from their previous estimate of []

Management to highlight novel oral biologics technology platform, clinical programs and research activities

SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that the company will

SOUTH SAN FRANCISCO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Hol

Top-line data readouts expected from four Phase 2 trials of oral AMT-101, consistent with previous guidance

The stock price of Applied Molecular Transport Inc. (NASDAQ: AMTI) increased by over 20% pre-market. This is why it happened.

Once daily, oral AMT-101 was safe and well tolerated, and demonstrated trends of improvement in objective measures of inflammation: fecal calprotectin, CRP, and histology

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.

SOUTH SAN FRANCISCO, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the closing of its pr

The stock price of Applied Molecular Transport Inc. (NASDAQ: AMTI) increased by 44.44% yesterday. This is why it happened.